- TheStreet.com•13 hours ago
Citigroup analysts say IMS Health (IMS) data show that Gilead's (GILD) hepatitis-C drug sales may be below forecasts.
- Kiplinger•13 hours ago
These 9 stocks come from different industries but share two things in common: They're well off all-time highs, and they won't be for long.
- Barrons.com•16 hours ago
Citigroup's Robyn Karnauskas and Mohit Bansal note that sales of Gilead Sciences' (GILD) hepatitis-C treatments look to be coming in below investor expectations. They explain: IMS scripts are down ~14.3% ...
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||79.63 x 700|
|Ask||79.77 x 200|
|Day's Range||79.27 - 80.33|
|52wk Range||77.92 - 113.31|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||7.00|
|Avg Vol (3m)||10,096,628|
|Dividend & Yield||1.88 (2.35%)|